- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
MedReleaf Obtains Good Manufacturing Practices Certification
MedReleaf announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.
MedReleaf (TSX:LEAF) announced it became the first medical cannabis producer to receive an International Council on Harmonization certification for Good Manufacturing Practices for Active Pharmaceutical Ingredients.
As quoted in the press release:
MedReleaf’s wide-ranging ICH-GMP compliance certification covers the Research and Development, Production, Distribution, Processing, Selling, and Destruction of medical cannabis for its Markham facility.
Although there are a number of different GMP certifying bodies, the ICH-GMP is the globally accepted standard for the pharmaceutical industry recognized by regulatory authorities around the world including Canada, the United States, EU, Japan, Singapore and Australia.
MedReleaf’s ICH-GMP certification will support the Company’s international growth and commitment to maintaining its position as the Medical Grade Standard in a number of ways, including:
- Providing the Company with a global manufacturing practice and platform that complies with GMP requirements around the world.
- Facilitating the sale of MedReleaf products to any global market allowing the import of medical cannabis.
- Accelerating MedReleaf’s partnerships with pharmaceutical and biotech companies as the only ICH-GMP certified producer of medical cannabis that can be used in late-stage clinical trials around the world.
Click here to read the full press release.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â